Soluble CD40 ligand induces human coronary artery smooth muscle cells proliferation and migration

Surgery

Volumn 146, Issue 1, 2009, Pages 5-11

  Chai, Hong ^a   Aghaie, Kamran ^a   Zhou, Wei ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; GELATINASE A; GELATINASE B; MESSENGER RNA; NEUTRALIZING ANTIBODY;

ARTICLE; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; CD40 LIGAND; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERPLASIA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; RNA, MESSENGER; TUNICA INTIMA;

EID: 67349206531     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.04.004     Document Type: Article

References (22)

1. Raines E.W., and Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 69 Suppl 1 (1993) S30-S37
2. Pauly R.R., Passaniti A., Bilato C., et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 75 (1994) 41-54
3. Cai X. Regulation of smooth muscle cells in development and vascular disease: current therapeutic strategies. Expert Rev Cardiovasc Ther 4 (2006) 789-800
4. Newby A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 69 (2006) 614-624
5. Raffetto J.D., and Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75 (2008) 346-359
6. Grewal I.S., and Flavell R.A. The CD40 ligand. At the center of the immune universe?. Immunol Res 16 (1997) 59-70
7. Koutroubakis I.E., Theodoropoulou A., Xidakis C., et al. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol 16 (2004) 1147-1152
8. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
9. Lutgens E., and Daemen M.J. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 12 (2002) 27-32
10. Andre P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 (2002) 896-899
11. Chai H., Yan S., Wang H., et al. CD40 ligand increases expression of its receptor CD40 in human coronary artery endothelial cells. Surgery 140 (2006) 236-242
12. Thienel U., Loike J., and Yellin M.J. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol 198 (1999) 87-95
13. Dechanet J., Grosset C., Taupin J.L., et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 159 (1997) 5640-5647
14. Mach F., Schonbeck U., Sukhova G.K., Atkinson E., and Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998) 200-203
15. Chen C., Chai H., Wang X., et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 112 (2008) 3205-3216
16. Kodali R.B., Kim W.J., Galaria II, et al. CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler Thromb Vasc Biol 24 (2004) 1211-1216
17. Escobar E., Rodriguez-Reyna T.S., Arrieta O., and Sotelo J. Angiotensin, II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2 (2004) 385-399
18. Flaxenburg J.A., Melter M., Lapchak P.H., Briscoe D.M., and Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol 172 (2004) 7503-7509
19. Urbich C., Dernbach E., Aicher A., Zeiher A.M., and Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106 (2002) 981-986
20. Hermann A., Schror K., and Weber A.A. CD40 ligand (CD40L) does not stimulate proliferation of vascular smooth muscle cells. Eur J Cell Biol 81 (2002) 213-221
21. Scudiero D.A., Shoemaker R.H., Paull K.D., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48 (1988) 4827-4833
22. Li G., Sanders J.M., Bevard M.H., et al. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 172 (2008) 1141-1152